General education about policies that impact pharmaceutical development approval and reimbursement; General education about FDA approval policies and NIH research activities. Education concerning pediatric rare diseases; Legislation affecting orphan drugs and rare diseases; Compassionate use policies and proposals; Medicare Payment Reform.
Tax issues affecting the pharmaceutical industry; Foreign direct investment; the Orphan Drug Tax Credit; Implementation of the Tax Cuts and Jobs Act (P.L. 115-97).
Medicare and Medicaid reimbursement policies and Part B payment reform; Policies impacting Medicare Part D.
Policies implemented pursuant to H.R. 1625, the Consolidated Appropriations Act.
Duration: April 1, 2010
to
March 4, 2019
General Issues: Health Issues , Taxation/Internal Revenue Code , Medicare/Medicaid , Budget/Appropriations , Homeland Security , Disaster Planning/Emergencies , Science/Technology
Spending: about $2,150,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2010: U.S. Senate, House of Representatives
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Karina Lynch Staff Member, Senate Committees on Aging and Gov. Affairs
Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov. Affairs.
Michael Beer Legislative Assistant, Representative Dave Hobson
Cheryl Jaeger Shared Employee, Ofice of Speaker & Ofc VA 7
Sr. Policy Adv, Majority Leader, Rep Cantor
Sr. Policy Adv, Republican Whip, Rep Cantor
Sr. Policy Adv, Majority Whip, Rep Blunt
Prof Staff House Committee on E&C
Sr. LA to Rep. Christopher Cox
Shared Employee, Ofc of Speaker & Ofc VA 7
Sr. Policy Adv, Majority Whip, Rep Blung
Sr. LA Rep. Christopher Cox
Shrs Employee, Ofc of the Speaker & Ofc of VA 7; Sr. Policy Adv, Maj Leader, Rep Cantor; Sr. Policy Adv, Rep Whip, Rep Cantor; Sr. Policy Adv, Maj Whip, Rep Blunt; Prof Staff House Committee on E&C; Sr. LA to Rep Cox
Shrd Employee, Ofc of the Speaker & Ofc of VA 7; Sr. Policy Adv, Maj Leader, Rep Cantor; Sr. Policy Adv, Rep Whip, Rep Cantor; Sr. Policy Adv, Maj Whip, Rep Blunt; Prof Staff House Committee on E&C; Sr. LA to Rep Cox
Andrew Jones Legislative Counsel, Rep Hinojosa; Legislative Director and Counsel, Rep Lujan
Legislative Counsel, Rep. Hinojosa; Legislative Director and Counsel, Rep. Lujan
Christopher Hatcher Sch. C, Treasury; LD, Rep. Scott McInnis
Jenny DiJames LA and LD, Rep. Bud Cramer
Susan Hirschmann COS, Rep. Van Hilleary and Majority Whip
COS, Rep.Van Hilleary and Majority Whip DeLay
COS, Rep Hilleary and Majority Whip
Joyce Rogers Rep. Steny Hoyer and Rep. Corrine Brown
Rebecca Anderson White House Office of Legislative Affairs
George Olsen n/a
Matthew Hoekstra n/a
J. Steven Hart n/a
Erin Book Mullen n/a
Melinda Maxfield n/a
Erin Book n/a
David Starr n/a
Bert Carp n/a
Robert Martinez n/a
Steve Hart n/a
J.Steven Hart n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2019
Williams and Jensen, PLLC terminated an engagement in which they represented Shire Pharmaceuticals LLC formerly known as Shire Regenerative Medicine on April 22, 2019.
Original Filing: 301034535.xml
Lobbying Issues
General education about policies that impact pharmaceutical development approval and reimbursement; General education about FDA approval policies and NIH research activities. Education concerning pediatric rare diseases; Legislation affecting orphan drugs and rare diseases; Compassionate use policies and proposals; Medicare Payment Reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues affecting the pharmaceutical industry; Foreign direct investment; the Orphan Drug Tax Credit; Implementation of the Tax Cuts and Jobs Act (P.L. 115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare and Medicaid reimbursement policies and Part B payment reform; Policies impacting Medicare Part D.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Policies implemented pursuant to H.R. 1625, the Consolidated Appropriations Act.
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, Williams and Jensen, PLLC lobbied for Shire Pharmaceuticals LLC formerly known as Shire Regenerative Medicine , earning $60,000. The report was filed on Jan. 18, 2019.
Original Filing: 301009046.xml
Lobbying Issues
Policies related to H.R. 1628, American Healthcare Act of 2017; General education about policies that impact pharmaceutical development approval and reimbursement; General education about FDA approval policies and NIH research activities. Education concerning pediatric rare diseases; legislation affecting orphan drugs and rare diseases; Compassionate use policies and proposals; Medicare Payment Reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues affecting the pharmaceutical industry; Foreign direct investment, orphan drug tax credit, tax issues; Implementation of H.R. 1, Tax Cuts and Jobs Act (P.L. 115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare and Medicaid reimbursement policies and Part B payment reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Policies impacting Medicare Part D. Policies relating to H.R. 1625, Consolidated Appropriations Act.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, Williams and Jensen, PLLC lobbied for Shire Pharmaceuticals LLC formerly known as Shire Regenerative Medicine , earning $60,000. The report was filed on Oct. 22, 2018.
Original Filing: 300994825.xml
Lobbying Issues
Policies related to H.R. 1628, American Healthcare Act of 2017; General education about policies that impact pharmaceutical development approval and reimbursement; General education about FDA approval policies and NIH research activities. Education concerning pediatric rare diseases; legislation affecting orphan drugs and rare diseases; Compassionate use policies and proposals; Medicare Payment Reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues affecting the pharmaceutical industry; Foreign direct investment, orphan drug tax credit, tax issues; Implementation of H.R. 1, Tax Cuts and Jobs Act (P.L. 115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare and Medicaid reimbursement policies and Part B payment reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Policies impacting Medicare Part D. Policies relating to H.R. 1625, Consolidated Appropriations Act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, Williams and Jensen, PLLC lobbied for Shire Pharmaceuticals LLC formerly known as Shire Regenerative Medicine , earning $40,000. The report was filed on July 18, 2018.
Original Filing: 300968246.xml
Lobbying Issues
Policies related to H.R. 1628, American Healthcare Act of 2017; General education about policies that impact pharmaceutical development approval and reimbursement; General education about FDA approval policies and NIH research activities. Education concerning pediatric rare diseases; legislation affecting orphan drugs and rare diseases; Compassionate use policies and proposals; Medicare Payment Reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues affecting the pharmaceutical industry; Foreign direct investment, orphan drug tax credit, tax issues; Implementation of H.R. 1, Tax Cuts and Jobs Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare and Medicaid reimbursement policies and Part B payment reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Policies impacting Medicare Part D. Policies relating to H.R. 1625, Consolidated Appropriations Act.
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
Williams and Jensen, PLLC amended a lobbying report for representation of Shire Pharmaceuticals LLC formerly known as Shire Regenerative Medicine in Q12018 on July 3, 2018.
Original Filing: 300962075.xml
Lobbying Issues
H.R. 1628, American Healthcare Act of 2017; General education about policies that impact pharmaceutical development approval and reimbursement; FDA Reauthorization Act of 2017; general education about FDA approval policies and NIH research activities. Education concerning pediatric rare diseases; legislation affecting orphan drugs and rare diseases; FDA priority review voucher program authorization; Compassionate use policies and proposals; Medicare Payment Reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues affecting the pharmaceutical industry; Foreign direct investment, orphan drug tax credit, tax issues; Implementation of H.R. 1, Tax Cuts and Jobs Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare and Medicaid reimbursement policies and Part B payment reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Policies impacting Medicare Part D, H.R. 1625, Consolidated Appropriations Act.
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, Williams and Jensen, PLLC lobbied for Shire Pharmaceuticals LLC formerly known as Shire Regenerative Medicine , earning $20,000. The report was filed on May 4, 2018.
Original Filing: 300959662.xml
Lobbying Issues
H.R. 1628, American Healthcare Act of 2017; General education about policies that impact pharmaceutical development approval and reimbursement; FDA Reauthorization Act of 2017; general education about FDA approval policies and NIH research activities. Education concerning pediatric rare diseases; legislation affecting orphan drugs and rare diseases; FDA priority review voucher program authorization; Compassionate use policies and proposals; Medicare Payment Reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues affecting the pharmaceutical industry; Foreign direct investment, orphan drug tax credit, tax issues; Implementation of H.R. 1, Tax Cuts and Jobs Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare and Medicaid reimbursement policies and Part B payment reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Policies impacting Medicare Part D, H.R. 1625, Consolidated Appropriations Act.
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, Williams and Jensen, PLLC lobbied for Shire Pharmaceuticals LLC formerly known as Shire Regenerative Medicine , earning $60,000. The report was filed on Jan. 18, 2018.
Original Filing: 300926773.xml
Lobbying Issues
H.R. 1628, American Healthcare Act of 2017; the better Care Reconciliation Act; General education about policies that impact pharmaceutical development approval and reimbursement; FDA Reauthorization Act of 2017; general education about FDA approval policies and NIH research activities. Education concerning pediatric rare diseases; legislation affecting orphan drugs and rare diseases; FDA priority review voucher program authorization; Compassionate use policies and proposals; Medicare Payment Reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues affecting the pharmaceutical industry; Foreign direct investment, orphan drug tax credit, tax reform, H.R. 1, Tax Cuts and Jobs Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare and Medicaid reimbursement policies and Part B payment reform.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2017
In Q3, Williams and Jensen, PLLC lobbied for Shire Pharmaceuticals LLC formerly known as Shire Regenerative Medicine , earning $60,000. The report was filed on Oct. 16, 2017.
Original Filing: 300904718.xml
Lobbying Issues
H.R. 1628, American Healthcare Act of 2017; the better Care Reconciliation Act; S. 204, Trickett Wendler Right to Try Act; H.R. 878 Right to Try; general education about policies that impact pharmaceutical development approval and reimbursement; H.R. 2430, S. 934, FDA Reauthorization Act of 2017; general education about FDA approval policies and NIH research activities. Education concerning pediatric rare diseases; legislation affecting orphan drugs and rare diseases; FDA priority review voucher program authorization; Compassionate use policies and proposals; Medicare Payment Reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues affecting the pharmaceutical industry; Foreign direct investment, orphan drug tax credit, tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare and Medicaid reimbursement policies and Part B payment reform.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, Williams and Jensen, PLLC lobbied for Shire Pharmaceuticals LLC formerly known as Shire Regenerative Medicine , earning $60,000. The report was filed on July 18, 2017.
Original Filing: 300887107.xml
Lobbying Issues
H.R. 1628, American Healthcare Act of 2017; the better Care Reconciliation Act; S. 204, Trickett Wendler Right to Try Act; H.R. 878 Right to Try; general education about policies that impact pharmaceutical development approval and reimbursement; H.R. 2430, S. 934, FDA Reauthorization Act of 2017; general education about FDA approval policies and NIH research activities. Education concerning pediatric rare diseases; legislation affecting orphan drugs and rare diseases; FDA priority review voucher program authorization; Compassionate use policies and proposals; Medicare Payment Reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues affecting the pharmaceutical industry; Foreign direct investment, orphan drug tax credit, tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare and Medicaid reimbursement policies and Part B payment reform.
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, Williams and Jensen, PLLC lobbied for Shire Pharmaceuticals LLC formerly known as Shire Regenerative Medicine , earning $60,000. The report was filed on April 14, 2017.
Original Filing: 300865442.xml
Lobbying Issues
H.R. 1628, American Healthcare Act of 2017. S. 204, H.R. 878 Right to Try legislation; general education about policies that impact pharmaceutical development approval and reimbursement; prescription drug user fee agreement and general education about FDA approval policies and NIH research activities. Education concerning pediatric rare diseases; legislation affecting orphan drugs and rare diseases; FDA priority review voucher program authorization; Compassionate use policies and proposals; Medicare Part B Payment Reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues affecting the pharmaceutical industry; Foreign direct investment, orphan drug tax credit, tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare and Medicaid reimbursement policies.
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, Williams and Jensen, PLLC lobbied for Shire Pharmaceuticals LLC formerly known as Shire Regenerative Medicine , earning $60,000. The report was filed on Jan. 17, 2017.
Original Filing: 300847615.xml
Lobbying Issues
H.R. 34, 21st Century Cures ACT (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee); provisions concerning pediatric rare diseases and DEA export issues; General health care reform; Issues related to attention deficit hyperactivity disorder (ADHD) medicines; legislation affecting orphan drugs and rare diseases; FDA priority review voucher program authorization; compassionate use policies and proposals; Medicare Part B Payment Reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues affecting the pharmaceutical industry; Foreign direct investment. Orphan Drug tax credit, tax reform; tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare and Medicaid reimbursement policies; S. 1865.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, Williams and Jensen, PLLC lobbied for Shire Pharmaceuticals LLC formerly known as Shire Regenerative Medicine , earning $60,000. The report was filed on Oct. 17, 2016.
Original Filing: 300828702.xml
Lobbying Issues
21st Century Cures Initiative (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee); provisions concerning pediatric rare diseases and DEA export issues; General health care reform; Issues related to attention deficit hyperactivity disorder (ADHD) medicines; legislation affecting orphan drugs and rare diseases; FDA priority review voucher program authorization; compassionate use policies and proposals; Medicare Part B Payment Reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues affecting the pharmaceutical industry; Foreign direct investment. Orphan Drug tax credit.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare and Medicaid reimbursement policies; S. 1865.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, Williams and Jensen, PLLC lobbied for Shire Pharmaceuticals LLC formerly known as Shire Regenerative Medicine , earning $60,000. The report was filed on July 14, 2016.
Original Filing: 300809589.xml
Lobbying Issues
21st Century Cures Initiative (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee); provisions concerning pediatric rare diseases and DEA export issues; General health care reform; Issues related to attention deficit hyperactivity disorder (ADHD) medicines; legislation affecting orphan drugs and rare diseases; FDA priority review voucher program authorization; compassionate use policies and proposals; Medicare Part B Payment Reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues affecting the pharmaceutical industry; Foreign direct investment.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare and Medicaid reimbursement policies; S. 1865.
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, Williams and Jensen, PLLC lobbied for Shire Pharmaceuticals LLC formerly known as Shire Regenerative Medicine , earning $60,000. The report was filed on April 18, 2016.
Original Filing: 300792707.xml
Lobbying Issues
21st Century Cures Initiative (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee); provisions concerning pediatric rare diseases and DEA export issues; General health care reform; Issues related to attention deficit hyperactivity disorder (ADHD) medicines; legislation affecting orphan drugs and rare diseases; FDA priority review voucher program authorization; compassionate use policies and proposals; Medicare Part B Payment Reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues affecting the pharmaceutical industry; Foreign direct investment.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare and Medicaid reimbursement policies; S. 1865.
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
In Q4, Williams and Jensen, PLLC lobbied for Shire Pharmaceuticals LLC formerly known as Shire Regenerative Medicine , earning $60,000. The report was filed on Jan. 19, 2016.
Original Filing: 300776313.xml
Lobbying Issues
21st Century Cures Initiative (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee); provisions concerning pediatric rare diseases and DEA export issues; General health care reform; Issues related to attention deficit hyperactivity disorder (ADHD) medicines; legislation affecting orphan drugs and rare diseases; FDA priority review voucher program authorization; possible pharmaceutical provisions in the Continuing Resolution and the Consolidated Appropriations Act, 2016; H.R. 2029.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues affecting the pharmaceutical industry.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare and Medicaid reimbursement policies; S. 1865; H.R. 2029.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2015
In Q3, Williams and Jensen, PLLC lobbied for Shire Pharmaceuticals LLC formerly known as Shire Regenerative Medicine , earning $60,000. The report was filed on Oct. 16, 2015.
Original Filing: 300754356.xml
Lobbying Issues
21st Century Cures Initiative (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee); provisions concerning pediatric rare diseases and DEA export issues; General health care reform; Issues related to attention deficit hyperactivity disorder (ADHD) medicines; legislation affecting orphan drugs and rare diseases; FDA priority review voucher program authorization.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues affecting the pharmaceutical industry.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare and Medicaid reimbursement policies; S. 1865.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2015
In Q2, Williams and Jensen, PLLC lobbied for Shire Pharmaceuticals LLC formerly known as Shire Regenerative Medicine , earning $60,000. The report was filed on July 16, 2015.
Original Filing: 300735901.xml
Lobbying Issues
21st Century Cures Initiative (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee); provisions concerning pediatric rare diseases and DEA export issues; General health care reform; Issues related to attention deficit hyperactivity disorder (ADHD) medicines; legislation affecting orphan drugs and rare diseases; FDA priority review voucher program authorization.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues affecting the pharmaceutical industry.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Medicare and Medicaid reimbursement policies.
Agencies Lobbied
U.S. Senate
1st Quarter, 2015
In Q1, Williams and Jensen, PLLC lobbied for Shire Pharmaceuticals LLC formerly known as Shire Regenerative Medicine , earning $60,000. The report was filed on April 13, 2015.
Original Filing: 300714593.xml
Lobbying Issues
21st Century Cures Initiative (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee); provisions concerning pediatric rare diseases and DEA export issues; General health care reform; Issues related to attention deficit hyperactivity disorder (ADHD) medicines; legislation affecting orphan drugs and rare diseases; FDA priority review voucher program authorization.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues affecting the pharmaceutical industry.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Rebates for Medicare Part D; Independent Payment Advisory Board (IPAB); potential drug industry issues in H.R. 2 the Medicare Access and CHIP Reauthorization Act.
Agencies Lobbied
U.S. Senate
4th Quarter, 2014
In Q4, Williams and Jensen, PLLC lobbied for Shire Pharmaceuticals LLC formerly known as Shire Regenerative Medicine , earning $50,000. The report was filed on Jan. 15, 2015.
Original Filing: 300696282.xml
Lobbying Issues
General health care reform; CMS coding coverage issues. Issues related to attention deficit hyperactivity disorder (ADHD) medicines; legislation affecting orphan drugs and rare diseases. Work on 21st Century Cures Initiative issues related to DEA; Implementation of the Patient Protection and Affordable Care Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
ACA implementation. Rebates for Medicare Part D. House and Senate action on H.J. Res. 59 and possible drug industry issues. Independent Payment Advisory Board (IPAB).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the pharmaceutical industry.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2014
In Q3, Williams and Jensen, PLLC lobbied for Shire Pharmaceuticals LLC formerly known as Shire Regenerative Medicine , earning $50,000. The report was filed on Oct. 17, 2014.
Original Filing: 300679365.xml
Lobbying Issues
General health care reform; CMS coding coverage issues. Issues related to attention deficit hyperactivity disorder (ADHD) medicines; legislation affecting orphan drugs and rare diseases.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
ACA implementation. Rebates for Medicare Part D. House and Senate action on H.J. Res. 59 and possible drug industry issues.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the pharmaceutical industry.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2014
In Q2, Williams and Jensen, PLLC lobbied for Shire Regenerative Medicine , earning $50,000. The report was filed on July 18, 2014.
Original Filing: 300660752.xml
Lobbying Issues
General health care reform; CMS coding coverage issues. Issues related to attention deficit hyperactivity disorder (ADHD) medicines; legislation affecting orphan drugs and rare diseases.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
ACA implementation. Rebates for Medicare Part D. House and Senate action on H.J. Res. 59 and possible drug industry issues.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the pharmaceutical industry.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2014
In Q1, Williams and Jensen, PLLC lobbied for Shire Regenerative Medicine , earning $60,000. The report was filed on April 18, 2014.
Original Filing: 300640700.xml
Lobbying Issues
General health care reform; CMS coding coverage issues. Issues related to attention deficit hyperactivity disorder (ADHD) medicines; legislation affecting orphan drugs adn rare diseases.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
CMS bundling rules for the hospital outpatient prospective payment system. ACA implementation. Rebates for Medicare Part D.
House and Senate action on H.J. Res. 59 and possible drug industry issues.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the pharmaceutical industry. Casey SGR amendment.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2013
In Q4, Williams and Jensen, PLLC lobbied for Shire Regenerative Medicine , earning $80,000. The report was filed on Jan. 16, 2014.
Original Filing: 300615822.xml
Lobbying Issues
General health care reform; CMS coding coverage issues. Issues related to attention deficit hyperactivity disorder (ADHD) medicines
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
CMS bundling rules for the hospital outpatient prospective payment system. ACA implementation. Rebates for Medicare Part D.
House and Senate action on H.J. Res. 59 and possible drug industry issues. The SGR Repeal and Medicare Beneficiary Access Improvement Act of 2013
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the pharmaceutical industry. Casey SGR amendment.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2013
In Q3, Williams and Jensen, PLLC lobbied for Shire Regenerative Medicine , earning $80,000. The report was filed on Oct. 18, 2013.
Original Filing: 300599204.xml
Lobbying Issues
General health care reform; CMS coding coverage issues.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
ACA implementation, rebates for Medicare Part D, House and Senate Budget proposals, CMS bundling rules for the hospital outpatient prospective payment system.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the pharmaceutical industry
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2013
In Q2, Williams and Jensen, PLLC lobbied for Shire Regenerative Medicine , earning $80,000. The report was filed on July 19, 2013.
Original Filing: 300577246.xml
Lobbying Issues
General health care reform; CMS coding coverage issues; Indian health issues.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
ACA implementations, rebates for Medicare Part D. House and Senate Budget resolutions.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the pharmaceutical industry
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2013
In Q1, Williams and Jensen, PLLC lobbied for Shire Regenerative Medicine , earning $80,000. The report was filed on April 22, 2013.
Original Filing: 300559724.xml
Lobbying Issues
General health care reform; CMS coding coverage issues; Indian health issues.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
ACA implementations, restates for Medicare Part D. House and Senate Budget resolutions; Continuing Resolution Appropriations for FY 2013 (H.R. 933)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax issues affecting the pharmaceutical industry
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2012
In Q4, Williams and Jensen, PLLC lobbied for Shire Regenerative Medicine , earning $80,000. The report was filed on Jan. 18, 2013.
Original Filing: 300532785.xml
Lobbying Issues
General health care reform; CMS coding coverage issues; Deficit Commission; Indian health issues.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
payment policy for diabetes product
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2012
In Q3, Williams and Jensen, PLLC lobbied for Shire Regenerative Medicine (formerly known as Advanced Biohealing) , earning $80,000. The report was filed on Oct. 18, 2012.
Original Filing: 300511634.xml
Lobbying Issues
General health care reform; CMS coding coverage issues; Deficit Commission; Indian health issues.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
payment policy for diabetes product
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2012
In Q2, Williams and Jensen, PLLC lobbied for Advanced Biohealing, Inc., a Shire company , earning $80,000. The report was filed on July 19, 2012.
Original Filing: 300491003.xml
Lobbying Issues
General health care reform; CMS coding issues; Deficit Commission, and Reauthorization of Prescription Drug User Fee Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
payment policy for diabetes product
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2012
In Q1, Williams and Jensen, PLLC lobbied for Advanced Biohealing, Inc. , earning $70,000. The report was filed on April 20, 2012.
Original Filing: 300470072.xml
Lobbying Issues
General health care reform; CMS coding issues; Deficit Commission, and Reauthorization of PDUFA.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
payment policy for diabetes product
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2011
In Q4, Williams and Jensen, PLLC lobbied for Advanced Biohealing, Inc. , earning $60,000. The report was filed on Jan. 20, 2012.
Original Filing: 300449595.xml
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
payment policy for diabetes product
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General health care reform; CMS coding issues; and Deficit Commission.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2011
In Q3, Williams and Jensen, PLLC lobbied for Advanced Biohealing, Inc. , earning $60,000. The report was filed on Oct. 20, 2011.
Original Filing: 300428316.xml
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
payment policy for diabetes product
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General health care reform; CMS coding issues; and Deficit Commission.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2011
In Q2, Williams and Jensen, PLLC lobbied for Advanced Biohealing, Inc. , earning $60,000. The report was filed on July 20, 2011.
Original Filing: 300405583.xml
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
payment policy for diabetes product
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General health care reform (Patient Protection and Affordable Care Act). CMS coding issue.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2011
In Q1, Williams and Jensen, PLLC lobbied for Advanced Biohealing, Inc. , earning $60,000. The report was filed on April 20, 2011.
Original Filing: 300374820.xml
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
payment policy for diabetes product
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General health care reform (Patient Protection and Affordable Care Act). CMS coding issue.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2010
In Q4, Williams and Jensen, PLLC lobbied for Advanced Biohealing, Inc. , earning $50,000. The report was filed on Jan. 20, 2011.
Original Filing: 300350406.xml
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
payment policy for diabetes product
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General health care reform (Patient Protection and Affordable Care Act). CMS coding issue.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2010
In Q3, Williams and Jensen, PLLC lobbied for Advanced Biohealing, Inc. , earning $50,000. The report was filed on Oct. 20, 2010.
Original Filing: 300325109.xml
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
payment policy for diabetes product
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General health care reform (Patient Protection and Affordable Care Act)
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2010
In Q2, Williams and Jensen, PLLC lobbied for Advanced Biohealing, Inc. , earning $30,000. The report was filed on July 20, 2010.
Original Filing: 300296921.xml
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
payment policy for diabetes product
Agencies Lobbied
U.S. House of Representatives
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...